TY - JOUR
AU - K. C. Osilla
AU - L. S. Meredith
AU - B. A. Griffin
AU - M. Martineau
AU - G. Hindmarch
AU - K. E. Watkins
A1 - 
AD - Stanford University School of Medicine, 1070 Arastradero Road, Palo Alto, CA 94304-5590, United States. Electronic address: kosilla@stanford.edu.; RAND Corporation, 1776 Main Street, Santa Monica, CA 90407, United States. Electronic address: seidel@rand.org.; RAND Corporation, 1200 South Hayes Street, Arlington, VA 22202, United States. Electronic address: bethg@rand.org.; RAND Corporation, 1200 South Hayes Street, Arlington, VA 22202, United States. Electronic address: monique@rand.org.; RAND Corporation, 1776 Main Street, Santa Monica, CA 90407, United States. Electronic address: ghindmar@rand.org.; RAND Corporation, 1776 Main Street, Santa Monica, CA 90407, United States. Electronic address: kwatkins@rand.org.
AN - 37454728
BT - Contemp Clin Trials
C5 - Opioids & Substance Use; Healthcare Disparities
DA - Sep
DO - 10.1016/j.cct.2023.107294
DP - NLM
ET - 20230716
JF - Contemp Clin Trials
LA - eng
PY - 2023
SN - 1551-7144 (Print); 1551-7144
SP - 107294
ST - Design of CLARO+ (Collaboration Leading to Addiction Treatment and Recovery from Other Stresses, Plus): A randomized trial of collaborative care to decrease overdose and suicide risk among patients with co-occurring disorders
T1 - Design of CLARO+ (Collaboration Leading to Addiction Treatment and Recovery from Other Stresses, Plus): A randomized trial of collaborative care to decrease overdose and suicide risk among patients with co-occurring disorders
T2 - Contemp Clin Trials
TI - Design of CLARO+ (Collaboration Leading to Addiction Treatment and Recovery from Other Stresses, Plus): A randomized trial of collaborative care to decrease overdose and suicide risk among patients with co-occurring disorders
U1 - Opioids & Substance Use; Healthcare Disparities
U3 - 10.1016/j.cct.2023.107294
VL - 132
VO - 1551-7144 (Print); 1551-7144
Y1 - 2023
ER -